Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.
Phase of Trial: Phase IV
Latest Information Update: 14 Dec 2016
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- 01 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
- 23 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2015 to 1 Apr 2016.
- 22 May 2013 Planned end date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.